Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results
Hims & Hers Health reported third-quarter 2026 results showing sales in line with estimates but full-year sales guidance below expectations, prompting a reduced profit forecast as margins contract. The company posted a surprise Q3 loss, and its stock extended losses after hours. WSJ reported climbing costs weighed on the outlook, while Reuters and Yahoo Finance confirmed the guidance cut and sales miss. Investors await details from the earnings call on cost drivers and the path to restored profitability.
Listen to Live Briefing
Real-time synthesized voice briefing Β· Live Feeds Desk
- β Hims & Hers reported Q3 2026 sales in line with estimates but full-year sales guidance missed expectations, according to Yahoo Finance and Investor's Business Daily.
- β The company cut its 2026 profit forecast as margins contracted, reported by Reuters and WSJ.
- β Hims & Hers posted a surprise Q3 loss, causing its stock to extend losses after hours, per Investor's Business Daily, Barron's, and Yahoo Finance.
What changed
Hims & Hers shifted from its prior full-year profit expectations to a lower forecast after reporting a surprise Q3 loss and missing full-year sales guidance.
Live updates
-
Hims & Hers Cuts Profit Forecast After Q3 Loss
Hims & Hers Health reported third-quarter 2026 results showing sales in line with estimates but full-year sales guidance below expectations, prompting a reduced profit forecast as margins contract. The company posted a surprise Q3 loss, and its stock extended losses after hours. WSJ reported climbing costs weighed on the outlook, while Reuters and Yahoo Finance confirmed the guidance cut and sales miss. Investors await details from the earnings call on cost drivers and the path to restored profitability.
Why it matters
The telehealth company had previously guided investors toward stronger full-year performance, making the downward revision a notable reversal. Third-quarter results arrived amid broader scrutiny of digital health valuations and marketing spend efficiency. Competitor LifeMD also lowered full-year guidance after weak quarterly sales, suggesting sector-wide pressure on telehealth margins. The earnings call commentary will determine whether the cost increase is temporary or structural.
What is confirmed
- Hims & Hers reported Q3 2026 sales in line with estimates but full-year sales guidance missed expectations, according to Yahoo Finance and Investor's Business Daily.
- The company cut its 2026 profit forecast as margins contracted, reported by Reuters and WSJ.
- Hims & Hers posted a surprise Q3 loss, causing its stock to extend losses after hours, per Investor's Business Daily, Barron's, and Yahoo Finance.
Still unconfirmed
- The specific dollar amount of the Q3 loss and the exact revised profit forecast have not been confirmed in the provided sources.
- Whether LifeMD's similar guidance cut reflects a broader telehealth sector trend remains unverified.
What to watch next
- Full-year 2026 profit forecast revision details from the earnings call transcript
- Q4 2026 marketing spend and margin trajectory
- Next quarterly earnings report and updated annual guidance
confidence 88%Sources used for this update (18)
- seekingalpha.com β Patient Capital Management Q3 2026 Commentary
- www.marketscreener.com β Global Stocks Fall on Higher Oil Prices, AI Pullback | MarketScreener
- www.nbcnews.com β Tracking the 2026 early vote
- www.foxnews.com β 2026 House Election Results
- markets.ft.com β T-Mobile Brings More to the Holiday Mix: Deals on the Season's Must-Have Tech, All-New T-Mix Plans and More β Company Announceme....
- HIMS investor relations β Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results
- WSJ β Hims & Hersβ Climbing Costs Weigh on Outlook
- Reuters β Hims & Hers cuts 2026 profit forecast as margins contract
- Yahoo Finance β Hims & Hers Health (NYSE:HIMS) posts Q3 2026 sales in line with estimates but full-year sales guidance misses expectations
- Investor's Business Daily β Hims' Roller Coaster Ride Continues With Surprise Losses, Light Sales And A Guidance Cut
- Yahoo Finance β Hims & Hers Health (HIMS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- Barron's β Hims & Hers Stock Extends Losses After Earnings Stumble
Community Sentiment: How do you assess this situation?
Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community